Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Twelve Patent Applications Related to RNAi

Premium
Editor’s note: This week’s IP Update includes patents and patent applications omitted from last week’s RNAi News due to technical difficulties.
 



 
Title: Potent Inhibition of Influenza Virus by Specifically Designed Short Interfering RNA
 
Number: 7,304,042
 
Filed: Feb. 15, 2007
 
Lead Inventor: Bijay Pal, California State Polytechnic University
 
The patent, its abstract states, “discloses siRNA sequences against the constant region of the influenza virus nucleoprotein gene.” The invention further includes one or more of defined siRNA sequences in the form of “an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a plasmid expressing intracellularly in animals including humans.
 
“In another aspect, the invention includes one or more of said siRNA sequences in the form of an AAV vector adapted to express intercellularly and establish a permanent inhibitory effect against influenza virus by integrating to the cellular chromosome of animals including humans,” the abstracts adds. “The invention also includes the administration to an animal including humans, in a therapeutically effective amount, at least one of said siRNA sequences.”
 



 
Title: microRNA Motifs
 
Number: 20070275392
 
Filed: Dec. 28, 2006
 
Lead Inventor: Yu-Ching Chang, Industrial Technology Research Institute, Taiwan
 
The patent application, its abstract states, claims ”methods of identifying microRNA motifs or microRNA precursors for a target gene or a set of target genes,” as well as “related computer-readable media.”
 



 
Title: Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism
 
Number: 20070275465
 
Filed: June 14, 2004 PCT Filed: June 14, 2004
 
Lead Inventor: Claudia Woppman, Alnylam Europe (Alnylam Pharmaceuticals)
 
“The invention concerns a method for the targeted selection of a double-stranded ribonucleic acid consisting of two single strands that exhibits increased effectiveness in inhibiting the expression of a target gene by means of RNA interference,” the patent application’s abstract states. In the dsRNA of the invention, “the sequences of the single strands of the dsRNA are selected in such a way that on both ends of the dsRNA the last complementary nucleotide pair is a G-C, or at least two of the last four complementary nucleotide pairs are G-C pairs.”
 
Additionally, the abstract states, the dsRNA “exhibits a single-stranded overhang consisting of 1 to 4 unpaired nucleotides at the first end, and no overhang at the second end, [while] the unpaired nucleotide of the single-stranded overhang that is directly adjacent to the last complementary nucleotide pair contains a purine base.”
 



 
Title: Therapeutic Compositions
 
Number: 20070275914
 
Filed: March 8, 2004 PCT Filed: March 8, 2004
 
Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals
 
The patent application, its abstract states, claims “therapeutic sRNA agents,” as well as methods of making and using them.
 
Specifically, the application claims an RNAi agent “comprising a sense sequence and an antisense sequence, wherein the sense sequence has one or more asymmetrical 2'-O alkyl modifications and the antisense sequence has one or more asymmetrical phosphorothioate modifications, and the antisense sequence targets a human apoB-100, glucose-6-phosphatase, or beta-catenin nucleic acid sequence.”
 



 
Title: RNA Capable of Suppressing Expression of Klf5 Gene
 
Number: 20070275917
 
Filed: July 29, 2004 PCT Filed: July 29, 2004
 
Lead Inventor: Ryozo Nagai, Kyowa Hakko Kogyo
 
According the patent application’s abstract, the invention comprises an RNA, specifically a dsRNA, “capable of suppressing the expression of KLF5 gene, which comprises a sequence consisting of 15 to 30 contiguous nucleotides of KLF5 mRNA and a sequence complementary to the sequence, and which has been designed from the nucleotide sequence of Kruppel-like factor 5 cDNA. … By transfecting the RNA or a vector for expression of the RNA into cells, the expression of KLF5 gene in the cells can be suppressed. The RNA or a vector for expression of the RNA can be used as a therapeutic agent for cardiovascular disease or cancer.”
 



 
Title: RNA Amidates and Thioamidates for RNAi
 
Number: 20070275919
 
Filed: Nov. 3, 2004 PCT Filed: Nov. 3, 2004
 
Lead Inventor: Sergei Gryaznov, Geron
 
The invention, according to the patent application’s abstract, “relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage … and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.”
 



 
Title: RNAi-Mediated Inhibition of IGF1R for Treatment of Ocular Angiogenesis
 
Number: 20070275922
 
Filed: Dec. 29, 2006
 
Lead Inventor: Jon Chatterton, Alcon
 
“RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization, and neovascular glaucoma, and for treating patients at risk of developing such conditions,” the patent application’s abstract states.
 



 
Title: Cationic Peptides for siRNA Intracellular Delivery
 
Number: 20070275923
 
Filed: Feb. 16, 2007
 
Lead Inventor: Lishan Chen, Nastech Pharmaceutical
 
According to its abstract, the patent application claims “a composition for delivery of a RNA molecule to a cell, comprising a double-stranded RNA molecule of about 15 to about 40 base pairs; and a polynucleotide delivery-enhancing peptide, comprising a region of alternating lysine and histidine residues, or of alternating D and L forms of arginine.”
 



 
Title: siRNA Targeting Dual Specificity Phosphate 5   
 
Number: 20070276135
 
Filed: June 4, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to DUSP5.”
 



 
Title: siRNA Targeting Serine/Threonine Kinase 12   
 
Number: 20070276136
 
Filed: June 15, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to STK12.”
 



 
Title: Compositions and Methods for Inhibiting Expression of Eg5 Gene
 
Number: 20070281899
 
Filed: March 30, 2007
 
Lead Inventor: David Bumcrot, Alnylam Pharmaceuticals
 
The invention, the patent application’s abstract states, “relates to a double-stranded ribonucleic acid for inhibiting the expression of the Eg5 gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.”
 



 
Title: Compositions and Methods for Lipid and Polypeptide-Based siRNA Intracellular Delivery
 
Number: 20070281900
 
Filed: May 2, 2007
 
Lead Inventor: Kunyuan Cui, Nastech Pharmaceutical
 
According to the patent application’s abstract, the invention comprises “a composition of an interfering RNA [made of] a double-stranded RNA molecule having a double-stranded region of from about 15 to about 40 base pairs, a peptide having a hydrophobic region and a cationic region, and a non-cationic phospholipid, and uses thereof.”
 



 
Title: RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions
 
Number: 20070281901
 
Filed: May 17, 2007
 
Lead Inventor: John Yanni, Alcon
 
The patent application, its abstract states, claims “RNA interference … for inhibition of tumor necrosis factor alpha by silencing TNF alpha cell-surface receptor TNF receptor-1 mRNA expression, or by silencing TNF alpha-converting enzyme mRNA expression. Silencing such … targets, in particular, is useful for treating patients having a TNF alpha.-related condition or at risk of developing a TNF alpha.-related condition such as the ocular conditions dry eye, allergic conjunctivitis, or ocular inflammation, or such as dermatitis, rhinitis, or asthma,” the abstract notes.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.